Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA’s Generics Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.
You may also be interested in...
Mylan Wins Right To Acquire Merck KGaA Generics Business For $6.7 Billion
Global footprint will allow U.S. generics firm to maximize its follow-on biologics strategy, CEO Coury says.
Mylan Wins Right To Acquire Merck KGaA Generics Business For $6.7 Billion
Global footprint will allow U.S. generics firm to maximize its follow-on biologics strategy, CEO Coury says.
Ranbaxy Makes "Practical" Bid For Merck KGaA's Generics Unit
Ranbaxy confirmed reports that it made a bid for Merck KGaA's generic drugs unit, but the Indian generics company maintained that the offer does not overvalue the Merck asset